Antisense oligonucleotide strategy reverses HNRNPH2-related neurodevelopmental disorder (IMAGE)
Caption
Published today in Science Translational Medicine, a preclinical antisense oligonucleotide study show promise of reversing ultrarare HNRNPH2-related neurodevelopmental disorder. Pictured left to right are co-author Hong Joo Kim, PhD, Department of Cell & Molecular Biology, corresponding author J. Paul Taylor, MD, PhD, St. Jude executive vice president, scientific director, Department of Cell & Molecular Biology chair and Pediatric Translational Neuroscience Initiative director, and first author Ané Korff, PhD, Department of Cell & Molecular Biology.
Credit
St. Jude Children's Research Hospital
Usage Restrictions
No cropping
License
Original content